New drug combo offers hope for hard-to-treat thyroid cancer
NCT ID NCT04061980
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether two targeted drugs (encorafenib and binimetinib) with or without an immunotherapy drug (nivolumab) can shrink or slow advanced thyroid cancer that has spread and no longer responds to standard radioactive iodine treatment. About 24 adults with a specific BRAF gene mutation will receive the drug combination to see if it is safe and effective. The goal is to find a new treatment option for this difficult-to-treat cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAF NP_004324.2:P.V600M are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Drug combo shows promise against rare brain tumor
- New hope for Hard-to-Treat thyroid cancer: drug XL092 enters human trials
- New hope for rare, aggressive thyroid cancer: drug combo shows promise
- Immunotherapy cocktail takes on deadly thyroid cancer
- New combo therapy tackles cancer in HIV patients
- New drug combo targets Hard-to-Treat thyroid cancer